Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · IEX Real-Time Price · USD
17.65
+0.03 (0.17%)
Mar 27, 2023, 4:00 PM EDT - Market closed

Stock Price Forecast

According to 19 stock analysts, the average 12-month stock price forecast for RCUS stock is $44.29, which predicts an increase of 150.93%. The lowest target is $23.23 and the highest is $73.5. On average, analysts rate RCUS stock as a buy.
Analyst Consensus: Buy
Target Low Average Median High
Price $23.23 $44.29 $41.82 $73.5
Change +31.61% +150.93% +136.94% +316.43%

Analyst Ratings

The average analyst rating for RCUS stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Oct '22Nov '22Dec '22Jan '23Feb '23Mar '23
Strong Buy 666666
Buy 91010101010
Hold 223333
Sell 000000
Strong Sell 000000
Total 171819191919

Financial Forecast

Revenue This Year
107.30M
from 112.00M
Decreased by -4.20%
Revenue Next Year
183.87M
from 107.30M
Increased by 71.36%
EPS This Year
-4.70
from -3.71
EPS Next Year
-3.95
from -4.70
Year 2018201920202021202220232024202520262027
Revenue
8.35M15.00M78.00M383.00M112.00M107.30M183.87M223.99M310.96M638.89M
Revenue Growth
491.15%
79.58%
420.00%
391.03%
-70.76%
-4.20%
71.36%
21.82%
38.83%
105.46%
EPS
-1.43-1.93-2.240.71-3.71-4.70-3.95-3.77-4.64-3.15
EPS Growth
----------
No. Analysts -----1413933

Revenue Forecast

Revenue 20232024202520262027
High 178.5M 350.0M 519.2M 616.0M 1.1B
Avg 107.3M 183.9M 224.0M 311.0M 638.9M
Low 78.4M 88.2M 81.7M 155.8M 300.9M

Revenue Growth

Revenue Growth 20232024202520262027
High
59.4%
226.2%
182.4%
175.0%
250.2%
Avg
-4.2%
71.4%
21.8%
38.8%
105.5%
Low
-30.0%
-17.8%
-55.6%
-30.4%
-3.2%

EPS Forecast

EPS 20232024202520262027
High -3.49 -1.93 -0.79 -4.78 -3.24
Avg -4.70 -3.95 -3.77 -4.64 -3.15
Low -5.39 -5.63 -6.30 -4.46 -3.03

EPS Growth

EPS Growth 20232024202520262027
High - - - - -
Avg - - - - -
Low - - - - -
Sources: Price target, rating and forecast data provided by Finnhub and sourced from Wall Street analysts and other sell-side and buy-side analysts and investors. Data disclaimer.